Clinical bottom line
Serum metabolomic profiling is an emerging tool that may enhance risk stratification and prognostication in patients with acute-on-chronic liver failure (ACLF). Early studies suggest that distinct metabolomic signatures correlate with disease severity, organ dysfunction, and post-transplant recovery, potentially outperforming traditional clinical scores. However, metabolomic profiling remains investigational, with limited standardization and validation across diverse patient populations. Clinicians should view current findings as hypothesis-generating and not yet ready for routine clinical decision-making.
What the evidence shows
ACLF is characterized by acute hepatic decompensation in patients with chronic liver disease, often accompanied by multi-organ failure and high short-term mortality. Traditional prognostic models such as the Model for End-Stage Liver Disease (MELD) and its variants provide useful but imperfect risk stratification (Zhang et al., 2019). Recent metabolomic studies have begun to elucidate the complex metabolic derangements underlying ACLF, offering novel biomarker candidates.
Faitot et al. (2019) performed comprehensive metabolomic profiling in ACLF and post-hepatectomy liver failure patients, identifying distinct metabolic fingerprints associated with disease severity. Their findings highlighted alterations in amino acid, lipid, and energy metabolism pathways that correlated with clinical outcomes, suggesting metabolomics could refine prognostication beyond conventional scores.
Xiang et al. (2026) integrated gut microbiota and serum metabolomic profiling in ACLF patients undergoing liver transplantation. They identified unique metabolite patterns linked to post-transplant recovery, implying that metabolomic signatures may also predict transplant outcomes and guide perioperative management.
Chen et al. (2020) analyzed serum exosomal RNA profiles in HBV-related ACLF, revealing differential expression of metabolic pathway-related transcripts, which may reflect systemic metabolic dysfunction in ACLF pathogenesis.
These studies collectively indicate that metabolomic profiling captures the systemic metabolic disturbances in ACLF and holds promise as a biomarker platform for early diagnosis, severity grading, and therapeutic monitoring.
Caveats and uncertainty
Despite promising data, several limitations temper enthusiasm for immediate clinical adoption. Most metabolomic studies in ACLF are small, single-center, and cross-sectional, limiting generalizability. There is considerable heterogeneity in metabolomic platforms, sample processing, and analytical methods, complicating reproducibility and standardization.
The dynamic nature of ACLF and its rapid clinical course require longitudinal metabolomic assessments, which remain scarce. Moreover, confounding factors such as concomitant infections, medications, and nutritional status can influence metabolomic profiles.
The incremental predictive value of metabolomics over established clinical scores and biomarkers has not been rigorously validated in large prospective cohorts. Integration with other emerging tools, such as rotational thromboelastometry for coagulation assessment (Ferdinande et al., 2025) and clinical prognostic models like PLiST (Angsubhakorn et al., 2026), requires further study.
Finally, the cost, accessibility, and turnaround time of metabolomic assays currently limit their feasibility in routine clinical practice.
How this may change practice
If validated, serum metabolomic profiling could become a valuable adjunct in ACLF management by enabling earlier identification of high-risk patients, guiding timing for liver transplantation or advanced therapies, and monitoring response to interventions.
Metabolomic biomarkers might complement existing clinical scores to improve prognostic accuracy and personalize treatment strategies. Integration with microbiome data and other omics approaches could further refine patient stratification.
In the near term, clinicians should remain informed about advances in metabolomic research and consider participation in clinical studies evaluating these biomarkers. Multidisciplinary collaboration between hepatologists, transplant teams, and laboratory scientists will be essential to translate metabolomic insights into clinical tools.